Oxigene, Inc.
Company Information

701 Gateway Blvd Ste 210
South San Francisco, CA, 94080 United States
(650) 635-7000

Top 3 Competitors

Unlock more access to Hoover’s!

  • Build customized email lists 24/7, based on your best customer profile.
  • Learn more about the companies you want to sell to. Hoover’s has reports on 85+ million companies and 900 industries. 65,000 data points are updated each day.
  • Get real insight written by real people – exclusive research and reviews by our in-house Editorial staff.
  • We can deliver our data to your desktop, to Excel, direct to your CRM, into your custom app, or via mobile.

Call (866) 473-3932 today to get started with a FREE TRIAL!


Oxigene, Inc. Company Profile

OXiGENE starves cancer to death. The company's drug candidate, Zybrestat, works by disrupting the functioning of blood vessels that deliver oxygen to tumors. Zybrestat is being investigated as a treatment for patients with ovarian cancer and other forms of cancer. OXiGENE is also working on a second-generation version of its oxygen-starving technology. OXiGene's strategy is to identify and license compounds from academic research centers and then shepherd the compounds through clinical trials. However, it has limited its in-house drug development operations, instead sponsoring research at academic and other research institutions or using contract research organizations.